An Inhibitory Anti-factor IX Antibody Effectively Reduces Thrombus Formation in a Rat Model of Venous Thrombosis
- 1 January 1999
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 82 (11) , 1443-1445
- https://doi.org/10.1055/s-0037-1614852
Abstract
Summary: An inhibitory anti-factor IX/IXa antibody (BC2) has been investigated as an anti-thrombotic agent in a rat venous thrombosis model. The treatment of rats post-injury with a single bolus dose of BC2 (3mg/kg, iv.) resulted in an ~4 fold reduction in venous thrombus mass (P = 0.043). This efficacy was matched by a minimal (50 fold. These results demonstrate that the anti-factor IX/IXa antibody (BC2), when compared to heparin, can effectively reduce venous thrombosis with less disruptive consequences on blood clotting.Keywords
This publication has 8 references indexed in Scilit:
- Low-Molecular-Weight HeparinCirculation, 1998
- Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis modelEuropean Journal of Vascular and Endovascular Surgery, 1998
- HEPARIN-INDUCED THROMBOCYTOPENIA, PARADOXICAL THROMBOEMBOLISM, AND OTHER SIDE EFFECTS OF HEPARIN THERAPYMedical Clinics of North America, 1998
- The inherited basis of venous thrombosisPathology, 1997
- Prophylaxis against Deep Venous Thrombosis and Pulmonary Embolism in Patients with StrokeVascular Medicine, 1996
- The Coagulation ExplosionCerebrovascular Diseases, 1995
- Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.Journal of Clinical Investigation, 1991
- Thrombocytopenia associated with low-molecular-weight heparinThe Lancet, 1991